# Montelukast in Parkinson Disease

> **NCT06113640** · PHASE2,PHASE3 · RECRUITING · sponsor: **Mostafa Bahaa** · enrollment: 60 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** levodopa-carbidopa
- **DRUG:** Montelukast

## Key facts

- **NCT ID:** NCT06113640
- **Lead sponsor:** Mostafa Bahaa
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-05
- **Primary completion:** 2026-11-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113640, "Montelukast in Parkinson Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06113640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*